Latest On Cocrystal Pharma, Inc (COCP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-31 18:34 EST | News | Cocrystal cleared to run Phase 1 trial for COVID-19 drug in Australia | N/A |  |
| 2023-05-15 22:25 EST | News | Cocrystal Pharma GAAP EPS of -$0.64 misses by $0.05 | N/A | |
| 2023-04-10 20:48 EST | News | Cocrystal Pharma completes $4M equity offering priced ATM | N/A | |
| 2023-03-29 10:52 EST | News | Cocrystal Pharma GAAP EPS of -$4.77 | N/A | |
| 2022-11-15 00:23 EST | News | Cocrystal Pharma GAAP EPS of -$0.70 misses by $0.21 | N/A | |
| 2022-10-24 20:18 EST | News | Cocrystal Pharma (COCP) Presents At Dawson James Securities 2022 Small Cap Growth Conference - Slideshow | N/A | |
| 2022-10-11 14:02 EST | News | Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19 | N/A | |
| 2022-08-15 13:11 EST | News | Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21 | N/A | |
| 2022-08-09 00:34 EST | News | Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK | N/A | |
| 2022-07-14 20:34 EST | News | Cocrystal Pharma completes single ascending dose of phase 1 study of influenza A drug | N/A | |
| 2022-05-11 21:27 EST | News | Cocrystal Pharma GAAP EPS of -$0.04 in-line | N/A | |
| 2022-04-21 16:55 EST | News | Cocrystal, NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studies | N/A | |
| 2022-04-12 10:04 EST | News | Cocrystal Pharma oral antiviral CC-42344 for influenza A shows safety in interim phase 1 data | N/A | |
| 2022-03-24 07:38 EST | News | Cocrystal Pharma GAAP EPS of -$0.16 in-line | N/A | |
| 2022-03-10 14:10 EST | News | Cocrystal Pharma begins dosing of antiviral CC-42344 in phase 1 influenza A trial | N/A | |
| 2022-01-27 12:40 EST | News | Cocrystal Pharma picks two oral antiviral candidates for COVID-19 | N/A | |
| 2021-12-22 14:42 EST | News | Cocrystal highlights antiviral effect of its protease inhibitors against Omicron | N/A | |
| 2021-11-02 14:10 EST | News | Warning: COCP is at high risk of performing badly | N/A | |
| 2021-11-01 17:21 EST | News | Cocrystal Pharma submits pre-IND package to FDA for COVID-19 candidate | N/A | |
| 2021-10-07 07:26 EST | News | Cocrystal Pharma receives Australian clearance to initiate Phase 1 study of CC-42344 | N/A | |
| 2021-09-21 14:50 EST | News | Cocrystal Pharma (COCP) Investor Presentation - Slideshow | N/A | |
| 2021-08-16 15:43 EST | News | Cocrystal Pharma EPS in-line | N/A | |
| 2021-07-29 16:18 EST | News | Cocrystal's stock jumps 25% after CDI-45205 shows encouraging antiviral activity against Delta, Gamma variants | N/A | |
| 2021-07-21 01:50 EST | News | Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants | N/A | |
| 2021-07-21 01:39 EST | News | Cocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021 | N/A | |
| 2021-07-21 01:35 EST | News | Cocrystal Pharma added to Russell Microcap Index | N/A | |
| 2021-05-05 13:54 EST | News | Cocrystal Pharma launches $40M stock offering | N/A | |
| 2021-05-03 20:15 EST | News | Cocrystal Pharma updates on COVID-19 antiviral development programs | N/A | |
| 2021-03-19 04:41 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-18 12:25 EST | Earnings Estimate | An EPS average of -$0.04 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-17 20:47 EST | News | Cocrystal Pharma EPS beats by $0.03, misses on revenue | N/A | |
| 2021-01-21 07:30 EST | News | Cocrystal Pharma (COCP) Investor Presentation -Slideshow | N/A | |
| 2021-01-19 11:00 EST | News | Cocrystal Pharma further develops influenza A/B antiviral compounds under collaboration with Merck | N/A | |
| 2021-01-11 16:09 EST | News | Cocrystal sees 2021 cash burn of $800k a month | N/A | |
| 2020-12-22 18:03 EST | News | Cocrystal Pharma to test CDI-45205 against coronaviruses | N/A | |
| 2020-12-13 03:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-06 17:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 11:31 EST | Analyst Rating | The Analyst Target Price has increased from $4.5 to $4.75. | Buy | |
| 2020-11-17 19:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 05:14 EST | News | Cocrystal Pharma misses on revenue | N/A | |
| 2020-11-17 03:35 EST | Earnings Estimate | An EPS average of -$0.04 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-13 11:38 EST | Analyst Rating | The Analyst Target Price has decreased from $4.67 to $4.5. | Neutral | |
| 2020-11-07 15:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-19 08:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-27 16:00 EST | News | Cocrystal trades in red; announces $10M bought deal offering | N/A | |
| 2020-08-27 15:59 EST | News | Cocrystal Pharma raises "bought deal" offering to $15M | N/A | |
| 2020-08-08 16:27 EST | Financials | Company financials have been released. | Neutral | |
About Cocrystal Pharma, Inc (COCP):
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX, Inc. The company is headquartered in Bothell, Washington.
General
- Name Cocrystal Pharma, Inc
- Symbol COCP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Last Split Factor1:30
- Last Split Date2018-01-24
- Fiscal Year EndDecember
- IPO Date2011-05-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.cocrystalpharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 39.86
- Price/Book (Most Recent Quarter) 2.34
- Enterprise Value Revenue 42.74
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.17
- Next Quarter EPS Estimate -$0.04
- Operating Margin -476%
- Return on Assets -14%
- Return on Equity -25%
- Revenue 2.01 million
- Earnings Per Share -$1.47
- Revenue Per Share $0.04
- Gross Profit 2.01 million
- Quarterly Earnings Growth 26.9%
View More
Highlights
- Market Capitalization 107.92 million
- EBITDA -3424000
- Analyst Target Price $4.75
- Book Value Per Share $0.75
View More
Share Statistics
- Shares Outstanding 71.47 million
- Shares Float 47.6 million
- % Held by Insiders 2904%
- % Held by Institutions 23.76%
- Shares Short 2.21 million
- Shares Short Prior Month 2.21 million
- Short Ratio 0.79
- Short % of Float 4%
- Short % of Shares Outstanding 3%
View More
Technicals
- Beta 0.91
- 52 Week High $2.48
- 52 Week Low $0.6
- 50 Day Moving Average 1.76
- 200 Day Moving Average 1.34
View More
Dividends
- Dividend Date 2018-01-24
- ExDividend Date N/A
- Dividend Yield 0%
View More
Cocrystal Pharma, Inc (COCP) Dividend Calendar:
COCP's last dividend payment was made to shareholders on January 24, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Cocrystal Pharma, Inc (COCP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $510000 | -$0.01 | -$0.04 | 75% |
| 2020-09-30 | 2020-11-13 | $N/A | -$0.05 | -$0.05 | 5.8% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.07 | -$0.04 | -65.5% |
| 2020-03-31 | 2020-05-13 | $461000 | -$0.05 | -$0.08 | 37.5% |
| 2019-12-31 | 2020-03-27 | $402000 | -$0.07 | -$0.07 | 6.57% |
| 2019-09-30 | 2019-11-12 | $492000 | -$0.07 | -$0.08 | 8.88% |
| 2019-06-30 | 2019-08-09 | $592000 | -$0.07 | -$0.07 | 3% |
| 2019-03-31 | 2019-05-10 | $5.08 million | $0.10 | -$0.08 | 225% |
| 2018-12-31 | 2018-12-31 | $N/A | $0.34 | -$0.08 | 525% |
| 2018-09-30 | 2018-11-09 | $N/A | -$0.06 | -$0.08 | 25% |
| 2018-06-30 | 2018-08-09 | $N/A | -$0.05 | -$0.07 | 28.57% |
| 2018-03-31 | 2018-05-10 | $N/A | -$0.06 | ||
| 2017-12-31 | 2018-03-21 | $N/A | $0.20 | ||
| 2017-09-30 | 2017-09-30 | $N/A | -$0.09 | ||
| 2017-06-30 | 2017-06-30 | $N/A | -$0.04 | ||
| 2017-03-31 | 2017-03-31 | $N/A | -$0.11 | ||
| 2016-12-31 | 2016-12-31 | $N/A | -$2.76 | ||
| 2016-09-30 | 2016-09-30 | $N/A | -$0.08 | ||
| 2016-06-30 | 2016-06-30 | $N/A | -$0.14 | ||
| 2016-03-31 | 2016-03-31 | $N/A | -$0.17 | ||
| 2015-12-31 | 2015-12-31 | $53000 | -$1.32 | ||
| 2015-09-30 | 2015-09-30 | $25000 | -$0.02 | ||
| 2015-06-30 | 2015-06-30 | $27000 | -$0.11 | ||
| 2015-03-31 | 2015-03-31 | $26000 | -$1.13 | ||
| 2014-12-31 | 2014-12-31 | $9000 | -$0.46 | ||
| 2014-09-30 | 2014-09-30 | $N/A | -$0.16 | ||
| 2014-06-30 | 2014-06-30 | $N/A | -$0.08 | ||
| 2014-03-31 | 2014-03-31 | $N/A | -$0.03 | ||
| 2013-09-30 | 2013-09-30 | -$1.98 | |||
| 2013-06-30 | 2013-06-30 | -$0.33 | |||
| 2013-03-31 | 2013-03-31 | -$0.70 |
Cocrystal Pharma, Inc (COCP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 971000 | N/A | N/A | 1.28 million | 958000 |
| Income Before Tax | -1.49 million | N/A | N/A | -1.99 million | -47.85 million |
| Selling General Administrative | 1.01 million | N/A | N/A | 1.14 million | 1.27 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -1.4 million | N/A | N/A | -1.91 million | -1.75 million |
| Operating Income | -1.47 million | N/A | N/A | -1.96 million | -1.82 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 510000 | N/A | N/A | 461000 | 402000 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | -25000 | N/A | N/A | -27000 | -46.02 million |
| Net Income From Continuing Operations | -1.49 million | N/A | N/A | -1.99 million | -47.85 million |
| Net Income Applicable to Common Shares | -1.49 million | -2.67 million | -3.5 million | N/A | -47.85 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -93000 | -1000 | N/A |
| Change to Liabilities | -290000 | 981000 | N/A | 306000 | 329000 |
| Total Cash Flow from Investing Activities | -19000 | -127000 | N/A | -1000 | -115000 |
| Net Borrowings | -9000 | -44000 | N/A | -55000 | -42000 |
| Total Cash Flow from Financial Activities | N/A | N/A | 16.55 million | 2.66 million | -42000 |
| Change to Operating Activities | -353000 | 61000 | N/A | 35000 | -106000 |
| Change in Cash | N/A | N/A | 14.27 million | 1.42 million | -1.48 million |
| Total Cash from Operating Activities | -3.06 million | -2.2 million | -2.19 million | -1.23 million | -1.32 million |
| Depreciation | N/A | N/A | 74000 | 71000 | 66000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 124000 | 146000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 64000 | 207000 | N/A | 46.08 million | 22000 |
| Capital Expenditures | N/A | N/A | 93000 | 1000 | 115000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 1.74 million | N/A | N/A | 2.41 million | 2.82 million |
| Total Stockholder Equity | 52.51 million | N/A | N/A | 40.43 million | 25.71 million |
| Other Current Liabilities | 61000 | 36000 | N/A | 34000 | 7000 |
| Total Assets | 54.24 million | N/A | N/A | 42.84 million | 28.53 million |
| Common Stock | 71000 | 69000 | 53000 | N/A | 36000 |
| Other Current Assets | 50000 | 125000 | N/A | N/A | N/A |
| Retained Earnings | -244.91 million | -243.42 million | -240.75 million | -237.25 million | -235.26 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | 46000 | 46000 | 35000 | N/A | 50000 |
| Cash | 33.01 million | N/A | N/A | 21.69 million | 7.42 million |
| Total Current Liabilities | 1.36 million | 2.61 million | N/A | 1.93 million | 2.29 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 1.09 million | 1.18 million | 1.25 million | N/A | 1.11 million |
| Total Current Assets | 34.02 million | 32.9 million | N/A | 22.58 million | 8.28 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 33.41 million | 31.09 million | 17.96 million | N/A | 6.62 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 1.08 million | 1.49 million | N/A | 922000 | 1.51 million |
Cocrystal Pharma, Inc (COCP) Chart:
Cocrystal Pharma, Inc (COCP) News:
Below you will find a list of latest news for Cocrystal Pharma, Inc (COCP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cocrystal Pharma, Inc (COCP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest COCP Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 6:38 PM EST | 100 | $0.3879 |
| Jun 13, 2022 6:39 PM EST | 100 | $0.3879 |
| Jun 13, 2022 2:05 PM EST | 500 | $0.38 |
Cocrystal Pharma, Inc (COCP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220012439/0001493152-20-012439-index.htm |
| 2020-04-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1412486/000000000020003571/0000000000-20-003571-index.htm |
| 2020-02-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000081413320000040/0000814133-20-000040-index.htm |
| 2020-03-03 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000081413320000047/0000814133-20-000047-index.htm |
| 2019-11-22 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1412486/000094480919000082/0000944809-19-000082-index.htm |
| 2020-03-10 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1412486/000094480920000009/0000944809-20-000009-index.htm |
| 2020-03-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000110465920029961/0001104659-20-029961-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000119312520029852/0001193125-20-029852-index.htm |
| 2020-02-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000119312520056539/0001193125-20-056539-index.htm |
| 2019-10-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016209/0001493152-19-016209-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016212/0001493152-19-016212-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016250/0001493152-19-016250-index.htm |
| 2019-10-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016270/0001493152-19-016270-index.htm |
| 2019-10-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016273/0001493152-19-016273-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016555/0001493152-19-016555-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315219016837/0001493152-19-016837-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315219019230/0001493152-19-019230-index.htm |
| 2020-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220001295/0001493152-20-001295-index.htm |
| 2020-01-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220001411/0001493152-20-001411-index.htm |
| 2020-01-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220001412/0001493152-20-001412-index.htm |
| 2020-01-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220001413/0001493152-20-001413-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220002638/0001493152-20-002638-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220002874/0001493152-20-002874-index.htm |
| 2020-02-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003124/0001493152-20-003124-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003315/0001493152-20-003315-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003365/0001493152-20-003365-index.htm |
| 2020-03-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003572/0001493152-20-003572-index.htm |
| 2020-03-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003659/0001493152-20-003659-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220003917/0001493152-20-003917-index.htm |
| 2020-03-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/0001493152-20-004916-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220004992/0001493152-20-004992-index.htm |
| 2020-04-17 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1412486/000149315220006643/0001493152-20-006643-index.htm |
| 2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220006703/0001493152-20-006703-index.htm |
| 2020-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220006885/0001493152-20-006885-index.htm |
| 2020-04-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220007143/0001493152-20-007143-index.htm |
| 2020-04-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1412486/000149315220007265/0001493152-20-007265-index.htm |
| 2020-04-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1412486/000149315220007278/0001493152-20-007278-index.htm |
| 2020-05-04 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1412486/000149315220007657/0001493152-20-007657-index.htm |
| 2020-05-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1412486/000149315220007658/0001493152-20-007658-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220008160/0001493152-20-008160-index.htm |
| 2020-05-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1412486/000149315220008291/0001493152-20-008291-index.htm |
| 2020-05-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1412486/000149315220008313/0001493152-20-008313-index.htm |
| 2020-05-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220008508/0001493152-20-008508-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220010746/0001493152-20-010746-index.htm |
| 2020-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011180/0001493152-20-011180-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011715/0001493152-20-011715-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011716/0001493152-20-011716-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011718/0001493152-20-011718-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011730/0001493152-20-011730-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011748/0001493152-20-011748-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011751/0001493152-20-011751-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011752/0001493152-20-011752-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220011937/0001493152-20-011937-index.htm |
| 2020-07-01 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220012398/0001493152-20-012398-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220012439/0001493152-20-012439-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220014811/0001493152-20-014811-index.htm |
| 2020-08-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220016778/0001493152-20-016778-index.htm |
| 2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220016784/0001493152-20-016784-index.htm |
| 2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220016799/0001493152-20-016799-index.htm |
| 2020-08-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1412486/000149315220016850/0001493152-20-016850-index.htm |
| 2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220016851/0001493152-20-016851-index.htm |
| 2020-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220018769/0001493152-20-018769-index.htm |
| 2020-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1412486/000149315220020718/0001493152-20-020718-index.htm |
| 2020-02-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1412486/000153561020000076/0001535610-20-000076-index.htm |
| 2020-05-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1412486/999999999520001143/9999999995-20-001143-index.htm |